


## Supporting Information

Figure S1. Comparison of phosphopeptide quantitation using one-charge-state vs multi-charge-state method



A, MS-based relative quantitation of phosphopeptides from BIK1 S233A. The phosphorylation level of a peptide from the mutant was relative to that from the wide-type (defined as 100%). Quantitation was based on peptide MS signals from either multiple charge states or a single charge state of the highest abundance. The phosphosite(s) of each peptide is indicated below individual columns. Error bars are STD from three independent experiments. B, extracted ion chromatograms (XICs) of the doubly charged peptide phosphorylated on S236 + T237 derived from WT and the mutant. C, XICs of the singly charged peptide with the same phosphosites as B derived from WT and the mutant. The relative ratio of this phosphopeptide was independent of the charge state used for quantitation.

**Figure S2. MS/MS spectra of identified BIK1 Ser/Thr-phosphorylated peptides**

Figure S2A. peptide sequence: NFRPDpSVIGEGFGCVFK phosphosite: S71




Figure S2B. peptide sequence: ALQQLQDNLGKpSQTNPVKdpTK phosphosite: S360 and T368




Figure S2C. peptide sequence: ALQQLQDNLGKPSQ**p**TNPVKD**p**TK phosphosite: T362 and T368




Figure S2D. peptide sequence: DGPMGDLSYV**p**STR phosphosite: S236




Figure S2E. peptide sequence: DGPMGDLpSYVpSTR phosphosite: S233+S236




Figure S2F. peptide sequence: DGPMGDLpSYVpSpTR phosphosite: S236+T237




Figure S2G. peptide sequence: **ApSNILLDADYNAK** phosphosite: S206




Figure S2H. peptide sequence: **pSFpTFNELK** phosphosite: S54+T56




Figure S2I. peptide sequence: VMGTYGYAAPEYMS**p**SGHLNAR phosphosite :S253




Figure S2J. peptide sequence: VMGTYGYAAPEYMS**pSp**SGHLNAR phosphosite :S252+S253




Figure S2K. peptide sequence: VMG**p**TYGYAAPEYMSSGHLNAR phosphosite: T242




Figure S2L. peptide sequence: EWLTEINYL**p**SGHNLVK phosphosite: S129




Figure S2M. peptide sequence:LD**p**TQYLPEEAVR phosphosite:T314




Figure S2N. peptide sequence:TEGEIL**p**SSSTPVK phosphosite: S48







Figure S2O. peptide sequence:TEGEILSpSTPVK phosphosite:S49



**Figure S3. MS/MS spectra of phosphopeptides identified from FLS2-CD treated by BIK1**

Figure S3A. peptide sequence: ILGFAWESGKpTK phosphosite: T941




Figure S3B. peptide sequence: ILGFAWEpSGKpTK phosphosite:S938




Figure S3C. peptide sequence: QRPTSLNDEDE**p**SQDMTLR phosphosite: S1084




Figure S3D. peptide sequence : EF**p**SAESDKWFYTEAK phosphosite: S906





Figure S3E. peptide sequence : VLDMELGD**p**SIVSLK phosphosite: S1115



**Figure S4. MS/MS spectra of Tyr-phosphorylated peptides identified from BIK1**

Figure S4A. peptide sequence: **GApYFKLPWFLR** phosphosite: Y168




Figure S4B. peptide sequence: **ASNILLDADpYNAK** phosphosite: pY214




Figure S4C. peptide sequence: **VMGTYGYAAPEpYMSSGHLNAR** phosphosite: pY250

